Newcomer anti-IL-33 makes strides in COPD

Nature Biotechnology, Published online: 07 May 2026; doi:10.1038/s41587-026-03136-x

AstraZeneca’s IL-33 antibody tozorakimab targets two distinct signaling pathways engaged in COPD: inflammation and epithelial dysfunction.